Skip metastasis of prostate cancer: diagnosis and treatment.
- Author:
Jun-Qi WANG
1
;
Wang LI
;
Qiang WANG
;
Kun LIU
;
Li-Jun MAO
;
Jia-Cun CHEN
;
Jun-Nian ZHENG
;
Xiao-Qing SUN
Author Information
- Publication Type:Case Reports
- MeSH: Aged; Humans; Liver Neoplasms; secondary; Lung Neoplasms; secondary; Male; Neoplasm Metastasis; Prostatic Neoplasms; diagnosis; pathology; therapy
- From: National Journal of Andrology 2009;15(12):1120-1123
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo improve the diagnosis and treatment of far advanced prostate cancer without clinically detectable bone metastasis.
METHODSCancer metastatic lesions were found in the liver and lungs respectively of two patients on routine medical examination, and only an abnormally elevated level of the serum prostate specific antigen (PSA) was observed in the following system examinations. The patients were diagnosed as having prostate cancer by prostate biopsy. MRI showed a discontinued prostate capsule, and ECT revealed no bone metastasis. Diagnostic treatment was conducted by giving LHRHa combined with antiandrogens. One of the patients underwent surgical castration at 12 months, and both received intensity modulated radiation therapy (80 Gy) at 15 and 18 months, respectively.
RESULTSThe metastatic lesions in the liver and lungs of the patients were either absent or significantly reduced after treated by maximal androgen blockade for 3 months, and all disappeared after 6 months'treatment, with the PSA level stabilized at less than 0.02 microg/L in one patient, and around 0.5 microg/L in the other. Antiandrogen treatment was suspended after radiotherapy. The results of liver, lung and bone scanning were normal during the 12-month follow-up, and the PSA level was below 1.0 microg/L.
CONCLUSIONRemote metastasis of prostate cancer may occur in ectosteal organs first, which deserves special attention. A combination of different treatment methods promises satisfactory results.